BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pregelj L, Hwang TJ, Hine DC, Siegel EB, Barnard RT, Darrow JJ, Kesselheim AS. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Affairs 2018;37:724-31. [DOI: 10.1377/hlthaff.2017.1580] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Mueller CM, Rao GR, Miller Needleman KI. Precision Medicines' Impact on Orphan Drug Designation. Clin Transl Sci 2019;12:633-40. [PMID: 31297924 DOI: 10.1111/cts.12667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lee SJC, Murphy CC, Gerber DE, Geiger AM, Halm E, Nair RG, Cox JV, Tiro JA, Skinner CS. Reimbursement Matters: Overcoming Barriers to Clinical Trial Accrual. Med Care 2021;59:461-6. [PMID: 33492049 DOI: 10.1097/MLR.0000000000001509] [Reference Citation Analysis]
3 Vokinger KN, Muehlematter UJ. Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018. Health Policy 2020;124:261-7. [PMID: 31882156 DOI: 10.1016/j.healthpol.2019.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. Am Soc Clin Oncol Educ Book 2019;39:374-87. [PMID: 31099613 DOI: 10.1200/EDBK_242229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
5 Neez E, Hwang TJ, Sahoo SA, Naci H. European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs. Clin Pharmacol Ther 2020;107:541-52. [PMID: 31591708 DOI: 10.1002/cpt.1669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Vreman RA, Belitser SV, Mota ATM, Hövels AM, Goettsch WG, Roes KCB, Leufkens HGM, Mantel-Teeuwisse AK. Efficacy gap between phase II and subsequent phase III studies in oncology. Br J Clin Pharmacol 2020;86:1306-13. [PMID: 32034790 DOI: 10.1111/bcp.14237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 2020;371:m3434. [PMID: 33028575 DOI: 10.1136/bmj.m3434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
8 Vreman RA, Naci H, Goettsch WG, Mantel-Teeuwisse AK, Schneeweiss SG, Leufkens HGM, Kesselheim AS. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clin Pharmacol Ther 2020;108:350-7. [PMID: 32236959 DOI: 10.1002/cpt.1835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
9 Leopold C, Haffajee RL, Lu CY, Wagner AK. The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts. J Law Med Ethics 2020;48:538-51. [PMID: 33021165 DOI: 10.1177/1073110520958879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Pregelj L, Hine DC, Kesselheim AS, Darrow JJ. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed. Clin Pharmacol Ther 2021. [PMID: 34048058 DOI: 10.1002/cpt.2318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Netw Open 2020;3:e203284. [PMID: 32315070 DOI: 10.1001/jamanetworkopen.2020.3284] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
12 Issa AM, Carleton B, Gerhard T, Filipski KK, Freedman AN, Kimmel S, Liu G, Longo C, Maitland-van der Zee AH, Sansbury L, Zhou W, Bartlett G. Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. Pharmacoepidemiol Drug Saf 2021;30:985-92. [PMID: 33715268 DOI: 10.1002/pds.5226] [Reference Citation Analysis]
13 Pregelj L, Hine DC, Oyola-Lozada MG, Munro TP. Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine. Trends Biotechnol 2020;38:943-7. [PMID: 32600777 DOI: 10.1016/j.tibtech.2020.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]